Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia

US-based cohort study of 88,605 hospitalisations for pneumonia did not find a mortality benefit for treatment with empirical anti –methicillin-resistant S aureus (MRSA) therapy vs standard antibiotics for any group of patients examined, even those with risk factors for MRSA.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news

Related Links:

Empirical anti-MRSA treatment is associated with an increased risk of 30-day mortality in patients hospitalized for pneumonia, compared with standard antibiotic therapy, according to a retrospective study.Reuters Health Information
Source: Medscape Pathology Headlines - Category: Pathology Tags: Pulmonary Medicine News Source Type: news
This cohort study compares 30-day mortality among adult patients hospitalized for pneumonia receiving empirical anti –methicillin-resistant Staphylococcus aureus (MRSA) therapy vs standard empirical antibiotic regimens.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
Objective: to study features of pulmonary complications in intravenous drug users (IDUs) with and without HIV.Materials and Methods: 149 patients (111 were males, mean age - 34,6±5,2 years)- IDUs diagnosed with pneumonia who were included in the study as they admitted to the hospital. HIV infection was verified in 112 (75%). 105 (70%) patients had viral hepatitis (B, C, B+C), 70 (47%) -tuberculosis.Results: In the presence of HIV infection, especially with severe immunosuppression of CD4+
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections Source Type: research
In this study, we investigated the efficacy of antibiotic therapies and the impact of S. aureus alpha-toxin in a model of lethal influenza virus and MRSA coinfection. We demonstrate that antibiotics primarily attenuate alpha-toxin-induced acute lethality, even though both alpha-toxin-dependent and -independent mechanisms significantly contribute to animal mortality after coinfection. Furthermore, we found that the protein synthesis-suppressing antibiotic linezolid has an advantageous therapeutic effect on alpha-toxin-induced lung damage, as measured by protein leak and lactate dehydrogenase (LDH) activity. Importantly, usi...
Source: Infection and Immunity - Category: Infectious Diseases Authors: Tags: Host Response and Inflammation Source Type: research
Conclusion: The selection of empirical antimicrobial therapy relates not only the institutions or unit-specific antibiogram but also the site of infection. We can further suggest continuing to do surveillance of antibiogram and prevalence of MDR organisms for infection control as well as for empirical therapy, part of the antimicrobial stewardship program based on yearly records to change the local hospital antibiotic policy.
Source: The Journal of Infection in Developing Countries - Category: Infectious Diseases Source Type: research
Abstract The use of a drug administration plan and therapeutic drug monitoring (TDM) based on pharmacokinetic-pharmacodynamic (PK-PD) analysis is important for the effective use of antimicrobial agents to treat infections. We focused on the use of beta-lactam agents, anti-methicillin-resistant Staphylococcus aureus (MRSA) agents, and an antifungal agent as antimicrobial agents and examined their efficacy in patients under special clinical conditions from the viewpoint of safety and TDM. Our PK-PD analysis of the use of an administration plan to set an optimum serum level for beta-lactam agents or anti-MRSA drugs f...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - Category: Drugs & Pharmacology Authors: Tags: Yakugaku Zasshi Source Type: research
Conclusion The results of our study demonstrate that robenidine is not suitable as a sole antimicrobial agent for the treatment of Gram-negative pathogen infections due to the lack of activity against the majority of Gram-negative isolates except for A. baumannii and A. calcoaceticus. However, we demonstrated in vitro efficacy against all selected Gram-negative organisms when robenidine was tested in combination with EDTA or PMBN, including against multidrug-resistant strains. Therefore, robenidine may be an appropriate candidate as a component of a combination preparation for the treatment of otitis externa in dogs. This...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
We report a case of concurrent development of active pulmonary tuberculosis and invasive pulmonary aspergillosis (IPA) in a patient who received therapy with infliximab for Crohn’s disease. He has been treated with antitubercular therapy and liposomal amphotericin B for 8 weeks. His clinical course was complicated by paroxysmal atrial fibrillation requiring maintenance therapy with amiodarone, respiratory failure due both to pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) and extended-spectrum beta-lactamases (ESBL)-producing Klebsiella pneumoniae and pleural effusion requiring chest drainage. ...
Source: IDCases - Category: Infectious Diseases Source Type: research
Conclusion: There is a high reported exposure to antibiotics and awareness of the problem of MDR pathogens. Despite personal worries, most of the participants indicated a reasonable, non-stigmatizing behavior toward carriers of MDR pathogens, and that every individual was responsible to avoid their spread. Introduction The development of antibiotic resistance is a major public health concern in Europe (European Centre for Disease Prevention and Control, 2017) and worldwide (World Health Organization [WHO], 2014). Antibiotic resistances cause longer hospital stays, increased mortality (Ott et al., 2010), and substan...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
DiscussionThe GRACE-VAP trial is expected to reveal whether Gram staining can reduce the use of broad-spectrum antibiotics without impairing patient outcomes and thereby provide evidence for an antibiotic selection strategy in patients with VAP.Trial registrationClinicaltrials.gov,NCT03506113. Registered on 29 March 2018.University Hospital Medical Information Network, UMIN000031933. Registered on 26 March 2018.
Source: Trials - Category: Research Source Type: clinical trials
More News: Antibiotic Therapy | Health | Infectious Diseases | MRSA | Pneumonia | Study | Superbugs